FDA Approves Otezla for Psoriatic Arthritis Treatment

The U.S. Food and Drug Administration has approved Otezla (apremilast) for the treatment of psoriatic arthritis in adults.

Manufactured by Summit, N.J.-based Celgene Corp., Otezla demonstrated improvements in symptoms of psoriatic arthritis, such as tender and swollen joints and physical function, in clinical trials.

More Articles on FDA Approvals:

FDA Approves Xolair for Chronic Hives
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars